Skip to main content
PMC home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2005 Oct;97(10 Suppl):11S–16S.

Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.

H Lynn Starr 1, Jason Kemner 1
PMCID: PMC2640623  PMID: 16350601

Abstract

The Formal Observation of Concerta versUs Strattera (FOCUS) study was conducted to assess, in children with ADHD, treatment outcomes with Concerta [OROS methylphenidate (MPH)], a once-daily controlled-release medication, and Strattera, (atomoxetine), a selective noradrenaline reuptake inhibitor, Because of the lack of data in minority groups treated for ADHD, the present subgroup analysis was conducted to determine the effectiveness and tolerability of ADHD treatments in African-American patients who were randomized to OROS MPH (n=125) or atomoxetine (n=58) during the FOCUS study. At the end of the study, the mean dose of OROS MPH was 32.8 +/- 10.9 mg and that of atomoxetine was 1.1 +/- 0.4 mg/kg. The results demonstrated that both treatments were associated with significant improvements in ADHD symptoms from baseline; however, patients who received OROS MPH demonstrated significantly greater improvements in total ADHD symptoms, inattentiveness and global improvement. The incidence of adverse events was similar in both treatment groups. OROS MPH and atomoxetine are effective and tolerable in the treatment of African Americans with ADHD, and significantly greater treatment responses were observed in patients receiving OROS MPH compared with those receiving atomoxetine over three weeks. Additional studies are needed to evaluate treatment response in this population.

Full text

PDF
15S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold L. Eugene, Elliot Michael, Sachs Larry, Bird Hector, Kraemer Helena C., Wells Karen C., Abikoff Howard B., Comarda Anne, Conners C. Keith, Elliott Glen R. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD. J Consult Clin Psychol. 2003 Aug;71(4):713–727. doi: 10.1037/0022-006x.71.4.713. [DOI] [PubMed] [Google Scholar]
  2. Brown R. T., Sexson S. B. A controlled trial of methylphenidate in black adolescents. Attentional, behavioral, and physiological effects. Clin Pediatr (Phila) 1988 Feb;27(2):74–81. doi: 10.1177/000992288802700204. [DOI] [PubMed] [Google Scholar]
  3. Corman Shelby L., Fedutes Bethany A., Culley Colieen M. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm. 2004 Nov 15;61(22):2391–2399. doi: 10.1093/ajhp/61.22.2391. [DOI] [PubMed] [Google Scholar]
  4. Crosby Ross D., Kolotkin Ronette L., Williams G. Rhys. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003 May;56(5):395–407. doi: 10.1016/s0895-4356(03)00044-1. [DOI] [PubMed] [Google Scholar]
  5. Greenhill Laurence L., Pliszka Steven, Dulcan Mina K., Bernet William, Arnold Valerie, Beitchman Joseph, Benson R. Scott, Bukstein Oscar, Kinlan Joan, McClellan Jon. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002 Feb;41(2 Suppl):26S–49S. doi: 10.1097/00004583-200202001-00003. [DOI] [PubMed] [Google Scholar]
  6. Kratochvil C. J., Bohac D., Harrington M., Baker N., May D., Burke W. J. An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001 Summer;11(2):167–170. doi: 10.1089/104454601750284072. [DOI] [PubMed] [Google Scholar]
  7. Kratochvil Christopher J., Heiligenstein John H., Dittmann Ralf, Spencer Thomas J., Biederman Joseph, Wernicke Joachim, Newcorn Jeffrey H., Casat Charles, Milton Denai, Michelson David. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002 Jul;41(7):776–784. doi: 10.1097/00004583-200207000-00008. [DOI] [PubMed] [Google Scholar]
  8. Kratochvil Christopher J., Heiligenstein John H., Dittmann Ralf, Spencer Thomas J., Biederman Joseph, Wernicke Joachim, Newcorn Jeffrey H., Casat Charles, Milton Denai, Michelson David. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002 Jul;41(7):776–784. doi: 10.1097/00004583-200207000-00008. [DOI] [PubMed] [Google Scholar]
  9. Michelson David, Allen Albert J., Busner Joan, Casat Charles, Dunn David, Kratochvil Christopher, Newcorn Jeffrey, Sallee F. Randy, Sangal R. Bart, Saylor Keith. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002 Nov;159(11):1896–1901. doi: 10.1176/appi.ajp.159.11.1896. [DOI] [PubMed] [Google Scholar]
  10. Michelson David, Allen Albert J., Busner Joan, Casat Charles, Dunn David, Kratochvil Christopher, Newcorn Jeffrey, Sallee F. Randy, Sangal R. Bart, Saylor Keith. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002 Nov;159(11):1896–1901. doi: 10.1176/appi.ajp.159.11.1896. [DOI] [PubMed] [Google Scholar]
  11. Samuel V. J., Biederman J., Faraone S. V., George P., Mick E., Thornell A., Curtis S., Taylor A., Brome D. Clinical characteristics of attention deficit hyperactivity disorder in African American children. Am J Psychiatry. 1998 May;155(5):696–698. doi: 10.1176/ajp.155.5.696. [DOI] [PubMed] [Google Scholar]
  12. Spencer T., Biederman J., Heiligenstein J., Wilens T., Faries D., Prince J., Faraone S. V., Rea J., Witcher J., Zervas S. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001 Fall;11(3):251–265. doi: 10.1089/10445460152595577. [DOI] [PubMed] [Google Scholar]
  13. Spencer Thomas, Heiligenstein John H., Biederman Joseph, Faries Douglas E., Kratochvil Christopher J., Conners C. Keith, Potter William Z. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002 Dec;63(12):1140–1147. doi: 10.4088/jcp.v63n1209. [DOI] [PubMed] [Google Scholar]
  14. Wilens Timothy, Pelham William, Stein Mark, Conners C. Keith, Abikoff Howard, Atkins Marc, August Gerald, Greenhill Laurence, McBurnett Keith, Palumbo Donna. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2003 Apr;42(4):424–433. doi: 10.1097/01.CHI.0000046814.95464.7D. [DOI] [PubMed] [Google Scholar]
  15. Wolraich M. L., Greenhill L. L., Pelham W., Swanson J., Wilens T., Palumbo D., Atkins M., McBurnett K., Bukstein O., August G. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001 Oct;108(4):883–892. doi: 10.1542/peds.108.4.883. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES